Interlace Medical wins FDA nod for fibroid treatment

October 28, 2009 by MassDevice staff

The Framingham, Mass.-based gynecological device maker wins 510(k) approval for its MyoSure minimally invasive system to remove uterine fibroids.

Interlace Medical wins FDA nod for fibroid treatment

Interlace Medical Inc. won 510(k) clearance from the Food & Drug Administration for its MyoSure fibroid removal system.

The Framingham, Mass.-based gynecological device maker said its hysteroscopic tissue removal system is a minimally invasive technique that allows for the removal of submucosal fibroids and polyps in a single, out-patient procedure. Submucosal fibroids are benign tumors that grow just beneath the endometrial lining of the uterus.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp